Literature DB >> 12679720

Rat organic anion transporter 3 (rOAT3) is responsible for brain-to-blood efflux of homovanillic acid at the abluminal membrane of brain capillary endothelial cells.

Shinobu Mori1, Hitomi Takanaga, Sumio Ohtsuki, Tsuneo Deguchi, Young-Sook Kang, Ken-Ichi Hosoya, Tetsuya Terasaki.   

Abstract

The mechanism that removes homovanillic acid (HVA), an end metabolite of dopamine, from the brain is still poorly understood. The purpose of this study is to identify and characterize the brain-to-blood HVA efflux transporter at the rat blood-brain barrier (BBB). Using the Brain Efflux Index method, the apparent in vivo efflux rate constant of [3H]HVA from the brain, k(eff), was determined to be 1.69 x 10(-2) minute(-1). This elimination was significantly inhibited by para-aminohippuric acid (PAH), benzylpenicillin, indoxyl sulfate, and cimetidine, suggesting the involvement of rat organic anion transporter 3 (rOAT3). rOAT3-expressing oocytes exhibited [3H]HVA uptake (K(m) = 274 micromol/L), which was inhibited by several organic anions, such as PAH, indoxyl sulfate, octanoic acid, and metabolites of monoamine neurotransmitters. Neurotransmitters themselves did not affect the uptake. Furthermore, immunohistochemical analysis suggested that rOAT3 is localized at the abluminal membrane of brain capillary endothelial cells. These results provide the first evidence that rOAT3 is expressed at the abluminal membrane of the rat BBB and is involved in the brain-to-blood transport of HVA. This HVA efflux transport system is likely to play an important role in controlling the level of HVA in the CNS.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12679720     DOI: 10.1097/01.WCB.0000050062.57184.75

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  47 in total

Review 1.  Apicobasal polarity of brain endothelial cells.

Authors:  Thomas Worzfeld; Markus Schwaninger
Journal:  J Cereb Blood Flow Metab       Date:  2015-10-06       Impact factor: 6.200

2.  Decreased blood-brain barrier permeability to fluorescein in streptozotocin-treated rats.

Authors:  Brian T Hawkins; Scott M Ocheltree; Kristi M Norwood; Richard D Egleton
Journal:  Neurosci Lett       Date:  2006-11-15       Impact factor: 3.046

Review 3.  Brain-to-blood transporters for endogenous substrates and xenobiotics at the blood-brain barrier: an overview of biology and methodology.

Authors:  Tetsuya Terasaki; Sumio Ohtsuki
Journal:  NeuroRx       Date:  2005-01

4.  Pharmacokinetic consequences of active drug efflux at the blood-brain barrier.

Authors:  Stina Syvänen; Rujia Xie; Selma Sahin; Margareta Hammarlund-Udenaes
Journal:  Pharm Res       Date:  2006-04-07       Impact factor: 4.200

Review 5.  Organic anion transporters of the SLC22 family: biopharmaceutical, physiological, and pathological roles.

Authors:  Ahsan N Rizwan; Gerhard Burckhardt
Journal:  Pharm Res       Date:  2007-03       Impact factor: 4.200

Review 6.  Active efflux across the blood-brain barrier: role of the solute carrier family.

Authors:  Hiroyuki Kusuhara; Yuichi Sugiyama
Journal:  NeuroRx       Date:  2005-01

Review 7.  Localization of brain endothelial luminal and abluminal transporters with immunogold electron microscopy.

Authors:  Eain M Cornford; Shigeyo Hyman
Journal:  NeuroRx       Date:  2005-01

Review 8.  The SLC22 Transporter Family: A Paradigm for the Impact of Drug Transporters on Metabolic Pathways, Signaling, and Disease.

Authors:  Sanjay K Nigam
Journal:  Annu Rev Pharmacol Toxicol       Date:  2018-01-06       Impact factor: 13.820

Review 9.  The organic anion transporter (OAT) family: a systems biology perspective.

Authors:  Sanjay K Nigam; Kevin T Bush; Gleb Martovetsky; Sun-Young Ahn; Henry C Liu; Erin Richard; Vibha Bhatnagar; Wei Wu
Journal:  Physiol Rev       Date:  2015-01       Impact factor: 37.312

10.  The dopamine metabolite 3-methoxytyramine is a neuromodulator.

Authors:  Tatyana D Sotnikova; Jean-Martin Beaulieu; Stefano Espinoza; Bernard Masri; Xiaodong Zhang; Ali Salahpour; Larry S Barak; Marc G Caron; Raul R Gainetdinov
Journal:  PLoS One       Date:  2010-10-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.